Patents by Inventor Andrew Simon Bell
Andrew Simon Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220073506Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.Type: ApplicationFiled: November 17, 2021Publication date: March 10, 2022Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Publication number: 20220064158Abstract: The invention provides inter alia compound as defined herein and its use in the prevention or treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, e.g. cancer.Type: ApplicationFiled: December 19, 2019Publication date: March 3, 2022Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Edward William TATE, Andrew Simon BELL
-
Publication number: 20210251995Abstract: The invention provides a compound of formula (I), or pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, wherein R1 is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered aromatic heterocycle; and R2 is an optionally substituted 5- or 6-membered aromatic heterocycle. Also provided are pharmaceutical compositions comprising a compound of formula (I).Type: ApplicationFiled: June 4, 2019Publication date: August 19, 2021Applicants: EXSCIENTIA LTD.,, EVOTEC INTERNATIONAL GMBHInventors: Andrew Simon BELL, Adrian Michael SCHREYER, Stephanie VERSLUYS
-
Publication number: 20210230169Abstract: The present invention relates to compounds and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.Type: ApplicationFiled: July 16, 2019Publication date: July 29, 2021Inventors: John Mark Francis Gardner, Andrew Simon Bell
-
Patent number: 11046700Abstract: The present invention relates to compounds of formula (1a), formula (1b), formula (1c) or formula (1d): or, or a pharmaceutically acceptable salt thereof, which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.Type: GrantFiled: January 15, 2018Date of Patent: June 29, 2021Assignee: Merck Patent GmbHInventors: John Mark Francis Gardner, Andrew Simon Bell
-
Publication number: 20200339586Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: ApplicationFiled: July 8, 2020Publication date: October 29, 2020Applicant: Imperial College Innovations LimitedInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Patent number: 10759804Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: GrantFiled: June 29, 2016Date of Patent: September 1, 2020Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Patent number: 10745401Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: GrantFiled: February 10, 2020Date of Patent: August 18, 2020Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
-
Publication number: 20200255432Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: ApplicationFiled: July 22, 2019Publication date: August 13, 2020Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Publication number: 20200172543Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.Type: ApplicationFiled: February 10, 2020Publication date: June 4, 2020Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Hidefumi YOSHINAGA, Yohei IKUMA, Junya IKEDA, Satoshi ADACHI, Harunobu MITSUNUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
-
Publication number: 20200123158Abstract: The present invention relates to novel compounds and pharmaceutically acceptable salts or solvates thereof which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.Type: ApplicationFiled: January 15, 2018Publication date: April 23, 2020Inventors: John Mark Francis Gardner, Andrew Simon Bell
-
Patent number: 10577363Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: GrantFiled: September 9, 2015Date of Patent: March 3, 2020Assignee: EPIZYME, INC.Inventors: Lorna Helen Mitchell, Andrew Simon Bell, Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Michael John Munchhof
-
Publication number: 20180370974Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).Type: ApplicationFiled: June 29, 2016Publication date: December 27, 2018Applicant: Imperial Innovations LimitedInventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
-
Publication number: 20170362217Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: September 9, 2015Publication date: December 21, 2017Applicant: EPIZYME, INC.Inventors: Lorna Helen MITCHELL, Andrew Simon BELL, Richard CHESWORTH, Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Michael John MUNCHHOF
-
Publication number: 20160355528Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: ApplicationFiled: August 19, 2016Publication date: December 8, 2016Applicant: VIIV HEALTHCARE UK LIMITEDInventors: Andrew Simon BELL, Iain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
-
Patent number: 9447116Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: GrantFiled: July 2, 2014Date of Patent: September 20, 2016Assignee: ViiV Healthcare UK LimitedInventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Publication number: 20140315927Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Andrew Simon Bell, lain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
-
Patent number: 8809363Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: GrantFiled: November 14, 2011Date of Patent: August 19, 2014Assignee: VIIV Healthcare UK LimitedInventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Patent number: 8772343Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R3, R4 and R5 are as defined in the description. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 6, 2011Date of Patent: July 8, 2014Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Manuel Perez-Pacheco, David James Rawson, Robert Ian Storer, Nigel Alan Swain
-
Patent number: 8685977Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 11, 2011Date of Patent: April 1, 2014Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Marcel John De Groot
